MRC1 and rectal cancer: Given the unprecedented effect of neoadjuvant immunotherapy in patients with dMMR/MSI-H rectal cancer, it is essential to determine MMR protein expression in all patients and, if dMMR/MSI-H status is confirmed, to initiate immunotherapy followed by non-surgical management if cCR is achieved.